Choreo LLC Sells 531 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Choreo LLC cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 18.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,423 shares of the specialty pharmaceutical company’s stock after selling 531 shares during the period. Choreo LLC’s holdings in Jazz Pharmaceuticals were worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $551,000. CX Institutional acquired a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $4,316,000. Envestnet Portfolio Solutions Inc. grew its position in shares of Jazz Pharmaceuticals by 38.9% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company’s stock worth $542,000 after buying an additional 1,223 shares during the period. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 63.7% during the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 395 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $1,888,000. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the subject of several analyst reports. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 price objective on the stock. Royal Bank Of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Piper Sandler reissued an “overweight” rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Morgan Stanley reduced their price objective on shares of Jazz Pharmaceuticals from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 22nd. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $181.64.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the sale, the chief executive officer owned 436,973 shares of the company’s stock, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan bought 1,621 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the completion of the acquisition, the director owned 101,621 shares of the company’s stock, valued at $10,466,963. The trade was a 1.62% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 2,500 shares of company stock worth $277,930. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Down 0.7%

Shares of JAZZ stock opened at $116.60 on Wednesday. The firm has a fifty day moving average of $110.48 and a 200-day moving average of $118.01. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a market capitalization of $7.06 billion, a price-to-earnings ratio of 15.55, a P/E/G ratio of 5.65 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm’s revenue was down .5% on a year-over-year basis. During the same period in the prior year, the company earned $2.68 EPS. As a group, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.